GSK investigates bribery claims in the Middle East


GlaxoSmithKline (GSK) has been accused of bribing doctors and healthcare officials in Iraq in emails leaked to the Wall Street Journal by a whistleblower.

The whistleblower claimed in emails that GSK had put 16 doctors and pharmacists in Iraq on its payroll as sales staff while they continued working for the government full time. They also alleged that one emergency care physician had insisted on prescribing GSK drugs even when they weren’t available at the hospital pharmacy, despite competitor products being in stock, and said that the firm had also paid for doctors and their families to go to conferences overseas.

GSK has said it is taking the allegations seriously, and has launched an investigation covering ‘several countries and business units’ in the region. Chinese authorities, meanwhile, continue to investigate the GSK corruption scandal in which several members of staff have been arrested over allegations that the company used over £300 million to bribe doctors and health officials in China.


Related Content

GSK’s China troubles continue

6 August 2014 Business

news image

Analysts say stings will only drive corruption into less visible channels

Transparency measures forced on pharma

30 September 2014 Feature

news image

Previous misdemeanours are compelling the pharmaceutical industry to be more open with financial information and clinical dat...

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Flowing rivers of mercury

7 January 2015 Feature

news image

Philip Ball investigates claims that the burial chamber of China’s first emperor contains rivers of shimmering mercury

Most Commented

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments

The big experiment

23 January 2015 Critical Point

news image

Plans to stop assessing school pupils’ practical work are the wrong solution to a genuine problem, says Mark Peplow